Betta Pharmaceuticals 贝达药业
20 significant filings since 29 May 2026: 6 on share pledge, 8 on equity incentive and 2 on share issue, and 4 other kinds. The latest, on 31 Aug 2026: 关于股东股份质押变动的公告. On 22 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 120.00% to 180.00% from the same period a year earlier.
自 29 May 2026 起有 20 份重大公告：share pledge 6 份、equity incentive 8 份、share issue 2 份，另有 4 类。最新一份（31 Aug 2026）：关于股东股份质押变动的公告。22 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 120.00% 至 180.00%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 18 Mar 2021 | 国金证券 | 王班 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Outperform 增持 | 25 Aug 2026 | 1 | — |
| 国金证券 | 甘坛焕 | Buy 买入 | 23 Aug 2026 | 2 | — |
| 东海证券 | 杜永宏 | Buy 买入 | 12 Aug 2026 | 1 | — |
| 长城国瑞证券 | 胡晨曦,魏钰琪 | Buy 买入 | 30 Apr 2026 | 1 | — |
| 华安证券 | 谭国超,任婉莹 | Buy 买入 | 2 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。